For the quarter ending 2025-09-30, VANI had -$4,166K decrease in cash & cash equivalents over the period. -$7,174K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,530 | -13,446 |
| Depreciation and amortization | 105 | 204 |
| Stock-based compensation | 276 | 741 |
| Non-cash lease expense | 39 | 114 |
| Fixed assets write-off | 0 | 0 |
| R&d tax credit incentive receivable | 170 | 241 |
| Prepaid expenses and other assets | -650 | -412 |
| Accounts payable | -759 | 933 |
| Accrued compensation expenses | 1 | 13 |
| Accrued expenses | 37 | 20 |
| Net cash used in operating activities | -6,351 | -11,250 |
| Purchases of property and equipment | 823 | 76 |
| Net cash used in investing activities | -823 | -76 |
| Issuance of common stock and warrants in connection with the securities purchase agreement, net of issuance costs | 0 | 0 |
| Issuance of common stock in connection with the 2025 private sales transaction, net of issuance costs | 2,593 | - |
| Gross proceeds from insurance premium loan | 355 | - |
| Issuance of common stock and warrants in connection with the sales agreement, net of issuance costs | - | 0 |
| Payments on insurancepremiumloan | 0 | -237 |
| Net issuance costs in connection with the sales agreement | - | 28 |
| Net proceeds from issuance of common stock in connection with the sales agreement, net of issuance costs | -28 | - |
| Net cash provided by financing activities | 2,948 | -265 |
| Effect of exchange rate changes on cash and cash equivalents | 60 | 33 |
| Net decrease increase in cash, cash equivalents and restricted cash | -4,166 | -11,558 |
| Cash and cash equivalents at beginning of period | 19,690 | - |
| Cash and cash equivalents at end of period | 3,966 | - |
Vivani Medical, Inc. (VANI)
Vivani Medical, Inc. (VANI)